- Home
- TNGX
as 10-04-2024 4:00pm EST
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
| Founded: | 2014 | Country: | United States |
| Employees: | 140 | City: | BOSTON |
| Market Cap: | 747.9M | IPO Year: | N/A |
| Target Price: | $15.14 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.15 - $13.01 | Next Earning Date: | 11-06-2024 |
| Revenue: | $42,509,000 | Revenue Growth: | 26.16% |
| Revenue Growth (this year): | 18.15% | Revenue Growth (next year): | -26.43% |
Stock Insider Trading Activity of Tango Therapeutics Inc. (TNGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Sep 13 '24 | Sell | $10.53 | 67,400 | $709,755.70 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Sep 5 '24 | Sell | $11.56 | 75,000 | $867,135.00 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Aug 27 '24 | Sell | $11.55 | 25,000 | $288,665.00 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Aug 16 '24 | Sell | $9.94 | 285,000 | $2,835,367.50 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 30 '24 | Sell | $9.85 | 235,000 | $2,316,494.00 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 26 '24 | Sell | $9.84 | 50,000 | $491,950.00 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 24 '24 | Sell | $9.84 | 300,599 | $2,955,931.29 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 22 '24 | Sell | $9.78 | 387,740 | $3,793,446.41 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 18 '24 | Sell | $9.81 | 191,490 | $1,878,478.60 | 16,859,075 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Jul 17 '24 | Sell | $9.79 | 550,171 | $5,386,339.14 | 16,859,075 |
Latest Tango Therapeutics Inc. News
TNGX Breaking Stock News: Dive into TNGX Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 09/05/2024
Business Wire
a month ago
Tango Therapeutics to Participate in Upcoming Investor Conferences
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 08/21/2024
TipRanks
2 months ago
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks
Simply Wall St.
2 months ago
Tango Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Business Wire
2 months ago
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 08/02/2024
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 07/29/2024
Compare TNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNGX Tango Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.